Provention Bio Resubmits Application for Teplizumab
Teplizumab is being evaluated to delay type 1 diabetes. The PDUFA date is August 17, 2022.
Provention Bio has resubmitted and the FDA has accepted the biologics license application (BLA) for teplizumab for the delay of type 1 diabetes (T1D). The FDA has assigned a user fee goal date of August 17, 2022. If approved, teplizumab, an anti-CD3 monoclonal antibody, will be the first disease-modifying therapy for type 1 diabetes.
In July 2021, the FDA had issued a complete response letter for the therapy, indicating they wanted to see a single, low-dose pharmacokinetic/pharmacodynamic (PK/PD) bridging study in healthy volunteers to compare planned commercial product with drug product originating from drug substance manufactured for historic clinical trials had failed to show PK comparability.
Related: The FDA Issues Complete Response Letter for Teplizumab
The company has competed the required study assessing pharmacokinetic comparability. During a pre-BLA meeting in January, the FDA proposed, and the company agreed, to use PK modeling to adjust the 14-day dosing regimen match the exposure of clinical material used in prior clinical trials by ensuring that the 90% confidence intervals for relevant PK parameters fall within the target 80% to 125% range.
Additionally, a separate Type A meeting with the FDA during which several considerations related to product quality that were cited in the CRL were discussed.
Provention Bio is currently evaluating teplizumab in patients with newly diagnosed insulin-dependent type 1 diabetes in the phase 3 PROTECT study. The company reached the target enrollment of 300 patients during the third quarter of 2021 and expect to report top-line data from the from this study in the second half of 2023.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
ICER Finds Insurers Struggled to Provide Fair Access for Obesity Drugs
December 19th 2024The Institute for Clinical and Economic Review assessed the formularies of 11 payers, covering 57 million people, to determine access for drugs that the organization had reviewed in 2022 for cost-effectiveness.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
